Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.
Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.
复制标题
DOI:
10.1002/cmdc.201700783
复制
发表时间:
2018-05-23
期刊:
影响因子:
3.4
通讯作者:
Thuss U
中科院分区:
文献类型:
--
作者:
Beck H;Jeske M;Thede K;Stoll F;Flamme I;Akbaba M;Ergüden JK;Karig G;Keldenich J;Oehme F;Militzer HC;Hartung IV;Thuss U
Small‐molecule inhibitors of hypoxia‐inducible factor prolyl hydroxylases (HIF‐PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF‐PH mimics hypoxia and leads to increased erythropoietin (EPO) expression and subsequently increased erythropoiesis. Herein we describe the discovery, synthesis, structure–activity relationship (SAR), and proposed binding mode of novel 2,4‐diheteroaryl‐1,2‐dihydro‐3H‐pyrazol‐3‐ones as orally bioavailable HIF‐PH inhibitors for the treatment of anemia. High‐throughput screening of our corporate compound library identified BAY‐908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85‐3934), a novel small‐molecule oral HIF‐PH inhibitor. Molidustat is currently being investigated in clinical phase III trials as molidustat sodium for the treatment of anemia in patients with CKD.
登录
查看更多内容
DOI:
10.1073/pnas.192342099
发表时间:
2002-10-15
影响因子:
11.1
作者:
Ivan, M;Haberberger, T;Kaelin, WG
通讯作者:
Kaelin, WG
影响因子:
3.7
作者:
Chan MC;Atasoylu O;Hodson E;Tumber A;Leung IK;Chowdhury R;Gómez-Pérez V;Demetriades M;Rydzik AM;Holt-Martyn J;Tian YM;Bishop T;Claridge TD;Kawamura A;Pugh CW;Ratcliffe PJ;Schofield CJ
通讯作者:
Schofield CJ
影响因子:
1.8
作者:
Marvalin, Cyrille;Denoux, Mireille;Azerad, Robert
通讯作者:
Azerad, Robert
影响因子:
4.2
作者:
McCullough, Peter A.;Barnhart, Huiman X.;Califf, Robert M.
通讯作者:
Califf, Robert M.
影响因子:
56.9
作者:
Bruick, RK;McKnight, SL
通讯作者:
McKnight, SL